Wall Street Zen downgraded shares of GSK (NYSE:GSK – Free Report) from a buy rating to a hold rating in a research report sent to investors on Saturday morning.
A number of other research analysts also recently issued reports on the company. HSBC upgraded GSK from a “reduce” rating to a “hold” rating in a report on Monday, July 6th. Citigroup initiated coverage on shares of GSK in a research note on Friday, July 24th. They set a “neutral” rating on the stock. Jefferies Financial Group raised GSK to a “strong-buy” rating in a report on Friday, July 17th. Royal Bank Of Canada restated an “outperform” rating on shares of GSK in a research report on Tuesday, June 9th. Finally, Weiss Ratings downgraded GSK from a “buy (b-)” rating to a “hold (c+)” rating in a report on Wednesday, July 29th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $53.00.
Get Our Latest Research Report on GSK
GSK Price Performance
GSK Increases Dividend
The company also recently declared a quarterly dividend, which will be paid on Thursday, October 8th. Shareholders of record on Friday, August 14th will be given a dividend of $0.4515 per share. This represents a $1.81 dividend on an annualized basis and a yield of 3.5%. This is an increase from GSK’s previous quarterly dividend of $0.44. The ex-dividend date of this dividend is Friday, August 14th. GSK’s payout ratio is currently 55.94%.
Institutional Trading of GSK
Several large investors have recently made changes to their positions in GSK. Brighton Jones LLC bought a new stake in GSK in the 4th quarter worth about $528,000. Prime Capital Investment Advisors LLC increased its holdings in GSK by 182.7% during the fourth quarter. Prime Capital Investment Advisors LLC now owns 30,188 shares of the pharmaceutical company’s stock valued at $1,480,000 after buying an additional 19,509 shares during the last quarter. Farther Finance Advisors LLC increased its stake in shares of GSK by 146.6% in the 4th quarter. Farther Finance Advisors LLC now owns 29,529 shares of the pharmaceutical company’s stock worth $1,448,000 after purchasing an additional 17,553 shares in the last quarter. Dorsey Wright & Associates bought a new position in shares of GSK in the first quarter worth about $2,522,000. Finally, PFA Pension Forsikringsaktieselskab bought a new stake in GSK during the 4th quarter worth approximately $6,385,000. 15.74% of the stock is currently owned by institutional investors and hedge funds.
GSK Company Profile
GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.
GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.
Further Reading
- Five stocks we like better than GSK
- SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
- Why Rare Earth Processing Could Be the Real 2027 Opportunity
- The S&P 493 Are Staging a Comeback—This Value ETF Offers Broad Exposure
- TSMC Insiders Are Buying the Pullback—But Is the Signal as Bullish as It Looks?
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.
